Merck seeks to develop novel T-cell engager therapies with TriTAC platform: GlobalData EP News Bureau Feb 5, 2024 The deal includes the novel HPN-217 and HPN-328 compounds, which are currently undergoing Phase II clinical trials for various…
First-in-class DLL3-targeting BiTE could be the next big player in SCLC treatment: GlobalData EP News Bureau Nov 13, 2023 The drug is forecast to achieve peak sales of $788 million by 2029
